Last updated on April 2017

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute myeloid leukemia | Leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Patients with advanced AML that harbors IDH1 mutation
    Patients are relapsed from or refractory to at least 1 previous line of therapy
    Good kidney and liver function
    Male or female patients
    Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
    Women must have a negative serum pregnancy test within 7 days prior to the first dose
    of study drug or be surgically or biologically sterile or postmenopausal

You may not be eligible for this study if the following are true:

  • Previously treated with any prior mIDH1 targeted therapy
    Extramedullary disease only
    History of clinically significant or active cardiac disease
    Active clinically significant infection
    Unresolved chronic toxicity of previous AML treatment
    Taking known strong cytochrome P450 (CYP) 2C8 inducers or inhibitors
    Pregnancy or breast-feeding

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.